|
Female, n (%)
|
279 (79.5)
|
268 (79.5)
|
|
Age, mean (SD), y
|
55.5 (11.5)
|
55.6 (11.4)
|
|
Range
|
23-88
|
23-88
|
|
Age group, n (%)
| | |
|
18-40 y
|
38 (10.8)
|
34 (10.1)
|
|
41-64 y
|
244 (69.5)
|
236 (70.0)
|
|
≥ 65 y
|
69 (19.7)
|
67 (19.9)
|
|
Race, n (%)
| | |
|
White
|
295 (84.0)
|
283 (84.0)
|
|
African American
|
35 (10.0)
|
33 (9.8)
|
|
Other
|
21 (6.0)
|
21 (6.2)
|
|
Weight, mean (SD), kg
|
84.9 (21.2)
|
84.9 (21.2)
|
|
Range
|
47-156
|
47-156
|
|
Height, mean (SD), cm
|
165.0 (9.6)
|
165.0 (9.6)
|
|
Range
|
130-198
|
130-198
|
|
RA clinical characteristics
|
|
Duration of RA, mean (SD), y
|
12.5 (9.7)
|
12.4 (9.6)
|
|
RA disease duration, n (%)
| | |
|
< 3 y
|
42 (12.0)
|
42 (12.5)
|
|
3-4 y
|
39 (11.1)
|
38 (11.3)
|
|
5-10 y
|
93 (26.5)
|
87 (25.8)
|
|
> 10 y
|
177 (50.4)
|
170 (50.4)
|
|
Prior rituximab treatment
|
|
No. of prior rituximab courses, n (%)
| | |
|
0
|
306 (87.2)
|
293 (86.9)
|
|
1
|
24 (6.8)
|
24 (7.1)
|
|
2
|
21 (6.0)
|
20 (5.9)
|
|
Months since most recent rituximab course, n
|
45
|
44
|
|
Mean (SD)
|
6.8 (0.9)
|
6.7 (0.9)
|
|
Range
|
5-9
|
5-9
|
|
Medication history
|
|
No. of prior anti-TNF agents, n (%)
| | |
|
0
|
4 (1.1)
|
4 (1.2)
|
|
1
|
187 (53.3)
|
182 (54.0)
|
|
2
|
116 (33.0)
|
108 (32.0)
|
|
≥ 3
|
44 (12.5)
|
43 (12.8)
|
|
Prior non–anti-TNF biologic DMARDs
| | |
|
Abatacept
|
17 (4.8)
|
16 (4.7)
|
|
Tocilizumab
|
12 (3.4)
|
12 (3.6)
|
|
MTX dose, mg/wk
| | |
|
Mean (SD)
|
17.4 (4.7)
|
17.3 (4.7)
|
|
Median (range)
|
17.5 (8–25)
|
17.5 (8–25)
|
|
Oral steroid use, n (%)
|
150 (42.7)
|
143 (42.4)
|
|
Oral steroid dose, mg/d
| | |
|
Mean (SD)
|
7.2 (3.4)
|
7.3 (3.4)
|
|
Median (range)
|
5 (2–25)
|
5 (2–25)
|
